The 36-month beta value for ZURA is at 0.11. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ZURA is 44.26M, and currently, shorts hold a 11.81% of that float. The average trading volume for ZURA on March 14, 2025 was 457.12K shares.
ZURA) stock’s latest price update
The stock of Zura Bio Ltd (NASDAQ: ZURA) has decreased by -12.20 when compared to last closing price of 1.23.Despite this, the company has seen a loss of -15.62% in its stock price over the last five trading days. businesswire.com reported 2025-02-24 that HENDERSON, Nev.–(BUSINESS WIRE)—- $ZURA #TeamZura–Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation.
ZURA’s Market Performance
Zura Bio Ltd (ZURA) has seen a -15.62% fall in stock performance for the week, with a -23.40% decline in the past month and a -60.87% plunge in the past quarter. The volatility ratio for the week is 10.08%, and the volatility levels for the past 30 days are at 9.63% for ZURA. The simple moving average for the past 20 days is -17.21% for ZURA’s stock, with a -66.44% simple moving average for the past 200 days.
Analysts’ Opinion of ZURA
Many brokerage firms have already submitted their reports for ZURA stocks, with Leerink Partners repeating the rating for ZURA by listing it as a “Outperform.” The predicted price for ZURA in the upcoming period, according to Leerink Partners is $15 based on the research report published on November 04, 2024 of the previous year 2024.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see ZURA reach a price target of $5. The rating they have provided for ZURA stocks is “Neutral” according to the report published on September 05th, 2024.
Piper Sandler gave a rating of “Overweight” to ZURA, setting the target price at $26 in the report published on May 03rd of the previous year.
ZURA Trading at -35.25% from the 50-Day Moving Average
After a stumble in the market that brought ZURA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.99% of loss for the given period.
Volatility was left at 9.63%, however, over the last 30 days, the volatility rate increased by 10.08%, as shares sank -23.40% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -56.80% lower at present.
During the last 5 trading sessions, ZURA fell by -15.62%, which changed the moving average for the period of 200-days by -80.85% in comparison to the 20-day moving average, which settled at $1.3045. In addition, Zura Bio Ltd saw -56.80% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ZURA starting from Thiara Parvinder, who sale 1,001,633 shares at the price of $2.73 back on Nov 25 ’24. After this action, Thiara Parvinder now owns 0 shares of Zura Bio Ltd, valued at $2,734,458 using the latest closing price.
Thiara Parvinder, the Director of Zura Bio Ltd, sale 3,800,000 shares at $2.70 during a trade that took place back on Sep 11 ’24, which means that Thiara Parvinder is holding 1,001,633 shares at $10,260,000 based on the most recent closing price.
Stock Fundamentals for ZURA
The total capital return value is set at -0.29. Equity return is now at value -41.44, with -30.52 for asset returns.
Currently, EBITDA for the company is -60.56 million with net debt to EBITDA at 3.74. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.36.
Conclusion
In conclusion, Zura Bio Ltd (ZURA) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
